Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Elena Beatriz Moiraghi"'
Autor:
François Xavier Mahon, Catherine Bouard, Timothy P. Hughes, Rafik Fellague-Chebra, Naoto Takahashi, Anna G. Turkina, Dong-Wook Kim, Mikhail Fominykh, Elena Beatriz Moiraghi, Jeffrey H. Lipton, Ranjan Tiwari, Franck E. Nicolini, Tomasz Sacha, Nelma Cristina D. Clementino
Publikováno v:
Leukemia. 35(6)
The ENESTop study evaluated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) in chronic phase who had received ≥3 years of tyrosine kinase inhibitor therapy and achieved sustained deep molecular response only after swi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27031c3d0fc6830beac25b1baa066c2c
https://pubmed.ncbi.nlm.nih.gov/33980976
https://pubmed.ncbi.nlm.nih.gov/33980976
Autor:
Arthur Moellmann-Coelho, Teresa Cristina Bortolheiro, Monia Lunghi, Eliana C M Miranda, Fernanda S Seguro, Monika Conchon, Israel Bendit, Natália N Gonçalves, Elena Beatriz Moiraghi, Dario Ferrero, Andrea Castelli, Carmen Fava, Renato Centrone, Carmino Antonio De Souza, Matteo Dragani, Patrizia Pregno, Ingrid Luise, Micaela Bergamaschi, Laura Fogliatto, Giuseppe Saglio, Gianluca Gaidano, Cristiane Pinna, Nelma D Clementino, Valentina Giai, Katia B Pagnano, Jaisson Bortolini, Gustavo Hr Magalhaes, A Cuttica
Publikováno v:
Blood. 132:46-46
Glivec was the first tyrosine kinase inhibitor (TKI) approved for chronic myeloid leukemia (CML) treatment and its efficacy has been demonstrated in a large number of trials. Generic formulations have been used recently as a more cost effective treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258b1c221e7a1c0182a617fe431a5f61
https://doi.org/10.1182/blood-2018-99-113718
https://doi.org/10.1182/blood-2018-99-113718
Autor:
Raquel Bengió, Elena Beatriz Moiraghi, Cristian Alberto Ferri, Mariana Selena Gonzalez, Irene Larripa, Michele Bianchini, Maria Fernanda Noriega
Background: Chronic myeloid leukemia (CML) is a hematological disorder that in rare cases, mainly in CML neutrophilic, presents the e19a2 rearrangement. The encoded product is a 230-KDa protein. Despite the remarkable responses to treatment of most p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e4057ffe85c2a9dc30ebf1ee4194d8a
Wiley Online Library
Wiley Online Library
Autor:
Isabel Annetta, Dante Intile, Mariel Ana Perez, María Jose Mela Osorio, Georgina Bendek, Julio M. Pose Cabarcos, Federico Sackmann, Isolda Fernandez, Ana Ines Varela, Silvina Palmer, Alicia Enrico, Elena Beatriz Moiraghi, Miguel A. Pavlovsky, Mariana Debus, Isabel Giere, Federico Andrés Klosowski, Carolina Pavlovsky, Andres L. Brodsky, Romina Mariano
Publikováno v:
Blood. 128:5445-5445
Introduction: Early reduction of BCR-ABL transcript level has been associated with improved outcomes in CML treatment. Inability to achieve early molecular response(MR) at 3 months (M3>10%) is considered a predictor factor for unfavourable outcome. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9888c0e97fbc5f90cbbb2aed5a4904a5
https://doi.org/10.1182/blood.v128.22.5445.5445
https://doi.org/10.1182/blood.v128.22.5445.5445
Autor:
Timothy P. Hughes, Rafik Fellague-Chebra, Anna G. Turkina, Vasily Shuvaev, Jolanta Dengler, Noam Benyamini, Nelma Cristina D. Clementino, Yu Jin, Dong-Wook Kim, Elena Beatriz Moiraghi, Sikander Ailawadhi, Naoto Takahashi, Tomasz Sacha, Ari Gnanasakthy, Francois-Xavier Mahon, Jeffrey H. Lipton, Franck-Emmanuel Nicolini, Patricia Brandt, Carla Boquimpani, Sandip Acharya
Publikováno v:
Blood. 128:1891-1891
Background: ENESTop (NCT01698905) is an ongoing, single-arm, phase 2 study evaluating treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) who achieved sustained molecular response 4.5 (MR4.5; BCR-A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053f767d045d08f47fb009a9dfd996c0
https://doi.org/10.1182/blood.v128.22.1891.1891
https://doi.org/10.1182/blood.v128.22.1891.1891
Autor:
Rafik Fellague-Chebra, Noam Benyamini, Jeffrey H. Lipton, Carla Boquimpani, Elena Beatriz Moiraghi, Yu Jin, Jolanta Dengler, Sandip Acharya, Timothy P. Hughes, Anna G. Turkina, Nelma Cristina D. Clementino, Francois-Xavier Mahon, Naoto Takahashi, Nancy Krunic, Tomasz Sacha, Franck E. Nicolini, Vasily Shuvaev, Sikander Ailawadhi, Dong-Wook Kim
Publikováno v:
Blood. 128:792-792
Background: ENESTop, an ongoing, single-arm, phase 2 study (ClinicalTrials.gov, NCT01698905), is the first trial specifically evaluating treatment-free remission (TFR; ie, stopping tyrosine kinase inhibitor [TKI] treatment without a loss of response)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a37d6b641a07b468dbf7c9e87c936a47
https://doi.org/10.1182/blood.v128.22.792.792
https://doi.org/10.1182/blood.v128.22.792.792
Autor:
Natalia Weich, Cristian Alberto Ferri, Carolina Pavlovsky, Elena Beatriz Moiraghi, Isabel Giere, Raquel Bengió, Irene Larripa, Ariela Freya Fundia
Publikováno v:
Blood. 126:5134-5134
Chronic myeloid leukemia (CML) is specifically associated with the t(9;22)(q34;q11) reciprocal translocation giving rise to the Philadelphia chromosome and the subsequent formation of the BCR/ABL1 fusion gene, encoding a constitutively active tyrosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb2dd66d561a094ba463f30e996eb84d
https://doi.org/10.1182/blood.v126.23.5134.5134
https://doi.org/10.1182/blood.v126.23.5134.5134
Autor:
Susana Garbiero, Alicia Enrico, Romina Laura Penalba, Maria Veronica Ventriglia, Martin Beccasese, Elena Beatriz Moiraghi, Maria Josefina Freitas, Ana Ines Varela, Marta Catalan, Catalina Abramovich, Miguel A. Pavlovsky, Carolina Pavlovsky, Raquel Bengió
Publikováno v:
Blood. 126:5149-5149
INTRODUCTION: Ponatinib is a potent TKI indicated in T315I mutated CML and not mutated CML resistant to other drugs. Deep responses were reported in PACE trial in patients who had failed all other TKIs in chronic and advanced phase CML with acceptabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::165a13dae5b11a2676d07cbf9ae42c6c
https://doi.org/10.1182/blood.v126.23.5149.5149
https://doi.org/10.1182/blood.v126.23.5149.5149
Autor:
Vagner O Duarte, Nelma Cristina D. Clementino, Nelson Spector, José Luis López, Eliana C M Miranda, Eduardo Cervera, Alicia Magarinos, Nelson Hamerschlak, Belinda Pinto Simões, Ernesto Fanilla, Katia B. Pagnano, Monika Conchon, Miguel A. Pavlovsky, Vaneuza Araujo Moreira Funke, Ricardo Pasquini, Israel Bendit, Carmino Antonio De Souza, Carolina Pavlovsky, Carla Boquimpani, Rosana A Silveira, Elena Beatriz Moiraghi, Jorge E. Cortes, Luis Meillon, Raquel Bengió, Vania Hungria
Publikováno v:
Blood. 118:1701-1701
Abstract 1701 Mutations within the BCR-ABL domain are the most frequent mechanism of imatinib (IM) resistance. The second generation inhibitors (SGI) are indicated for imatinib intolerance or resistance and the initials trials showed similar response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::675b2e0568ed1633bbfab9ef1b404a52
https://doi.org/10.1182/blood.v118.21.1701.1701
https://doi.org/10.1182/blood.v118.21.1701.1701
Autor:
Juan Carlos Camargo García, Elena Beatriz Moiraghi, Eduardo Bullorsky, Carlos A. Doti, German Stemmelin, Hector Murro, María Gabriela Flores
Publikováno v:
Blood. 112:4267-4267
Background: Since the introduction of Imatinib (IM), the treatment of chronic myeloid leukemia (CML) experienced its most important change. As this drug became the first line for the treatment of CML, we learned that under-dosing was associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1486b32e9a6fb1f5b674f219bee394d8
https://doi.org/10.1182/blood.v112.11.4267.4267
https://doi.org/10.1182/blood.v112.11.4267.4267